HAEK:F:F-Haemato AG (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 15.8

Change

0.00 (0.00)%

Market Cap

USD 0.08B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZOE:F Zoetis Inc

N/A

USD 72.16B
MRK:F Merck & Company Inc

N/A

USD 67.61B
MRKC:F MERCK KGAA NAM.SP.ADR

N/A

USD 65.62B
TKD:F Takeda Pharmaceutical Company ..

N/A

USD 38.84B
TKDA:F Takeda Pharmaceutical Company ..

N/A

USD 38.72B
H6D0:F Haleon PLC

N/A

USD 35.13B
H6D:F Haleon PLC

N/A

USD 35.12B
TEV:F Teva Pharmaceutical Industries..

N/A

USD 17.10B
NB3:F Neurocrine Biosciences Inc

N/A

USD 13.12B
SH0:F Shionogi & Co. Ltd

N/A

USD 12.81B

ETFs Containing HAEK:F

XDIV:CA iShares Core MSCI Canadia.. 6.52 % 0.11 %

N/A

CAD 1.17B
FAI:CA 5.05 % 1.14 %

N/A

N/A
DXM:CA 3.51 % 0.67 %

N/A

N/A
FCCD:CA Fidelity Canadian High Di.. 3.22 % 0.00 %

N/A

CAD 0.16B
SCHC Schwab International Smal.. 0.47 % 0.12 %

N/A

USD 3.95B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -41.48% 12% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.48% 12% F 7% C-
Trailing 12 Months  
Capital Gain -12.71% 53% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.71% 50% F 33% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.68% 61% D- 43% F
Dividend Return -1.68% 57% F 39% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 22.92% 61% D- 51% F
Risk Adjusted Return -7.34% 59% D- 41% F
Market Capitalization 0.08B 47% F 29% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector